Investigating Severe Acute Respiratory Syndrome (SARS)
NCT00066209 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2017-07-02
Summary
Severe Acute Respiratory Syndrome (SARS) is a newly recognized illness that can be fatal.
The purpose of this study is to better understand SARS by collecting samples of blood and other body fluids of people who have been exposed to SARS or who are suspected to have the illness.
Up to 300 volunteers aged 18 years or older will be enrolled in this study. Participants will donate blood samples and, if appropriate, samples of fluid from the lungs, nose, or throat. Researchers will test these samples for proteins that control or mediate inflammatory or immune responses. The patterns of these proteins will reveal how SARS affects the body and the efforts the body makes to fight off the infection.
Conditions
- SARS Virus
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2003-08-04
- Completion
- 2007-05-24
Countries
- United States
Study Locations
More Related Trials
-
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.
NCT04259892 ·Status: COMPLETED
-
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992 ·Status: COMPLETED ·Phase: PHASE1
-
Convalescent Plasma in the Treatment of COVID 19
NCT04343261 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma Therapy - Zurich Protocol
NCT04869072 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
NCT04392232 ·Status: COMPLETED ·Phase: PHASE2
-
Surveillance of Individuals Following SARS-CoV-2 Infection
NCT04383444 ·Status: COMPLETED
-
Effect of Nasopharyngeal Wash With Normal Saline on SARS-CoV2 Viral Load
NCT05525832 ·Status: COMPLETED ·Phase: NA
-
A Longitudinal Study of COVID-19 Sequelae and Immunity
NCT04411147 ·Status: ACTIVE_NOT_RECRUITING
-
Intermediate IND Severe Illness COVID-19 CP
NCT04411602 ·Status: WITHDRAWN ·Phase: PHASE1
-
Plasma Therapy of COVID-19 in Severely Ill Patients
NCT04359810 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
NCT04292340 ·Status: UNKNOWN
-
Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease
NCT04542967 ·Status: COMPLETED ·Phase: PHASE2
-
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
NCT04498377 ·Status: TERMINATED ·Phase: PHASE2
-
Convalescent Plasma as a Possible Treatment for COVID-19
NCT04442191 ·Status: RECRUITING ·Phase: PHASE2
-
Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection
NCT04408209 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
NCT04516811 ·Status: TERMINATED ·Phase: PHASE3
-
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
NCT04421404 ·Status: COMPLETED ·Phase: PHASE2
-
Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19
NCT05271929 ·Status: TERMINATED ·Phase: PHASE3
-
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)
NCT04394884 ·Status: WITHDRAWN
-
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy
NCT04361253 ·Status: TERMINATED ·Phase: PHASE3
-
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19
NCT04425837 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
NCT04354831 ·Status: COMPLETED ·Phase: PHASE2
-
Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19
NCT04360278 ·Status: COMPLETED
-
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360486 ·Status: NO_LONGER_AVAILABLE
-
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
NCT04373460 ·Status: COMPLETED ·Phase: PHASE2